Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

6.86
+0.28004.26%
Volume:3.44M
Turnover:23.20M
Market Cap:778.62M
PE:-2.51
High:6.90
Open:6.51
Low:6.41
Close:6.58
52wk High:8.90
52wk Low:2.25
Shares:113.50M
Float Shares:58.41M
Volume Ratio:1.35
T/O Rate:5.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7367
EPS(LYR):-2.2987
ROE:-205.81%
ROA:-38.43%
PB:20.71
PE(LYR):-2.98

Loading ...

Robust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS

TIPRANKS
·
Feb 17

BUZZ-U.S. STOCKS ON THE MOVE-Ormat Technologies, Accenture, Kinsale Capital

Reuters
·
Feb 17

COMPASS Pathways Triumph In Hard To Treat Depression Ignites Investor Frenzy

Benzinga_recent_news
·
Feb 17

Analysts Conflicted on These Healthcare Names: Sensus Healthcare (SRTS), NeoGenomics (NEO) and COMPASS Pathways (CMPS)

TIPRANKS
·
Feb 17

Top Premarket Gainers

MT Newswires Live
·
Feb 17

Compass' psychedelic-based depression treatment scores second late-stage study win

Reuters
·
Feb 17

Compass Pathways Shares Jump 30% Premarket After Co's Depression Drug Meets Main Goal in Second Late‑Stage Trial

THOMSON REUTERS
·
Feb 17

BUZZ-Compass Pathways jumps as depression treatment study meets main goal

Reuters
·
Feb 17

BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin

Reuters
·
Feb 17

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating Comp360 Psilocybin for Treatment-Resistant Depression

THOMSON REUTERS
·
Feb 17

Compass Pathways Plc - Requests FDA Meeting for Rolling Submission

THOMSON REUTERS
·
Feb 17

Compass Pathways Plc - Comp360 Shows Well-Tolerated and Safe Profile

THOMSON REUTERS
·
Feb 17

Compass Pathways Announces New Phase 3 Data for Psilocybin in Depression

Reuters
·
Feb 16

Compass Pathways to Announce New Clinical Data From Two Ongoing Phase 3 Trials

THOMSON REUTERS
·
Feb 16

BUZZ-Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say

Reuters
·
Feb 04

RBC Raises Price Target on COMPASS Pathways to $21 From $16, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 23

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Intuitive Surgical (ISRG) and Sanofi (OtherSNYNF)

TIPRANKS
·
Jan 23

Compass Pathways Plc : RBC Raises Target Price to $21 From $16

THOMSON REUTERS
·
Jan 23

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Jan 08

RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Jan 08